ALGOS PHARMACEUTICAL CORP
SC 13G, 1997-02-26
PHARMACEUTICAL PREPARATIONS
Previous: SECURITY CAPITAL ATLANTIC INC, 10-K, 1997-02-26
Next: ALGOS PHARMACEUTICAL CORP, SC 13G, 1997-02-26






<PAGE>
 
<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                  SCHEDULE 13G
                                 (RULE 13D-102)
             INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND 13D-2
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934


                        ALGOS PHARMACEUTICAL CORPORATION
                                (NAME OF ISSUER)


                     COMMON STOCK, PAR VALUE $.01 PER SHARE
                         (TITLE OF CLASS OF SECURITIES)


                                   015869 10 0
                                 (CUSIP NUMBER)


















                                Page 1 of 5 pages




<PAGE>
 
<PAGE>



                                              13G


CUSIP NO.   015869 10 0
            -----------

1.   NAME OF REPORTING PERSON:
           Gilbert Goldstein
          ---------------------------------------------------------------------

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
                                                             (A) [  ]
                                                             (B) [  ]

3.   SEC USE ONLY

4.   CITIZENSHIP OR PLACE OF ORGANIZATION:
            United States citizen
          ---------------------------------------------------------------------

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
WITH:

5.   SOLE VOTING POWER:
                                      47,500
                   ------------------------------------------------------------

6.   SHARED VOTING POWER:
                                     809,250
                   ------------------------------------------------------------


7.   SOLE DISPOSITIVE POWER:
                                      47,500
                   ------------------------------------------------------------

8.   SHARED DISPOSITIVE POWER:
                                     809,250
                   ------------------------------------------------------------


9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
     PERSON:
                                     856,750
                   ------------------------------------------------------------

10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
     CERTAIN SHARES:
                         [  ]


11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9:
                                                     5.5%
                   ------------------------------------------------------------

12.  TYPE OF REPORTING PERSON:
                      IN
                    -----------------------------------------------------------



                                     Page 2 of 5 pages





<PAGE>
 
<PAGE>



ITEM 1.

     (a)    Name of Issuer:  Algos Pharmaceutical Corporation

     (b)    Address of Issuer's Principal Executive Offices:

                     Collingwood Plaza, 4900 Route 33
                     Neptune, New Jersey 07753-6804


ITEM 2.

     (a)    Name of Person Filing:  Gilbert Goldstein

     (b)    Address of Principal Business Office:

                     Algos Pharmaceutical Corporation
                     Collingwood Plaza, 4900 Route 33
                     Neptune, New Jersey 07753-6804

     (c)    Citizenship:  United States

     (d)    Title of Class of Securities:

                     Common Stock, $.01 par value

     (e)    CUSIP Number:  015869 10 0

ITEM 3.     Not applicable.

ITEM 4.     OWNERSHIP

     (a)    Amount Beneficially Owned:  856,750

     (b)    Percent of Class:  5.5%

     (c)    Number of shares as to which such person has:

            (i)           sole power to vote or to direct the vote:
                                        47,500
                          -----------------------------------------------------

            (ii)          shared power to vote or to direct the vote:
                                       809,250
                          -----------------------------------------------------

            (iii)         sole power to dispose or to direct the
                          disposition of:
                                        47,500
                          -----------------------------------------------------

            (iv)          shared power to dispose or to direct the
                          disposition of:
                                       809,250
                          -----------------------------------------------------



                                Page 3 of 5 pages





<PAGE>
 
<PAGE>




ITEM 5.     OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

            Not applicable.

ITEM 6.     OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

            Of the shares reported by Mr. Goldstein,  809,250 shares are held in
            a  trust  for  which  Mr.   Goldstein  holds  the  shared  power  of
            disposition and the power to vote.

ITEM 7.     IDENTIFICATION  AND  CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
            THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

            Not applicable.

ITEM 8.     IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

            Not applicable.

ITEM 9.     NOTICE OF DISSOLUTION OF GROUP:

            Not applicable.

ITEM 10.    CERTIFICATION:

            Not applicable.






                                Page 4 of 5 pages






<PAGE>
 
<PAGE>


                                    SIGNATURE


         After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

Date:   February 24, 1997




                                       \s\ Gilbert Goldstein
                                       ----------------------------------------
                                       Gilbert Goldstein
















                                Page 5 of 5 pages




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission